Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2. (Cancelled)

3. (Currently amended) ~~The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein~~

A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

Ar is phenyl, pyridyl, pyrimidyl, indolyl, quinolinyl, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, or imidazolyl; or oxides thereof when Ar is a heteroaryl;

Y is -C_{3-4}cycloalkyl(C_{1-4}alkyl)$_m$-COOH, wherein the C_{3-4}cycloalkyl is optionally substituted with halogen, alkoxy, hydroxy or nitrile, and the (C_{1-4}alkyl) substituents are optionally linked to form a C_{3-4}cycloalkyl ; wherein n is 0, 1, 2, 3 or 4, m is 0, 1 or 2;

R is H or –C_{1-6}alkyl;

R^1 is H, or –C_{1-6}alkyl, –C_{3-6}cycloalkyl, –C_{1-6}alkoxy, –C_{2-6}alkenyl, –C_{3-6}alkynyl, heteroaryl, or heterocycle group, optionally substituted with 1-3 independent haloC_{1-6}alkyl, -C_{1-6}alkyl, –C_{1-6}alkoxy, OH, amino, –(C_{0-6}alkyl)–SO_p–(C_{1-6}alkyl), nitro, CN, =N-O-C_{1-6}alkyl, -O-N=C_{1-6}alkyl, or halogen substituents, wherein p is 0, 1 or 2;

R^2 is H, halogen, -CN, $-NO_2$, $-C_{1-6}$alkyl, $-C_{3-6}$cycloalkyl, -O- C_{3-6}cycloalkyl, O-C_{1-6}alkyl, O-C_{3-6}cycloalkyl-C_{1-6}alkyl(C_{3-6}cycloalkyl)(C_{3-6}cycloalkyl), $-C_{1-6}$alkoxy, phenyl, heteroaryl, heterocycle, amino, $-C(O)-C_{1-6}$alkyl, $-C(O)-O-C_{1-6}$alkyl, $-C_{1-6}$alkyl(=N-OH), -C(N=NOH)C_{1-6}alkyl, $-C_{0-6}$alkyl(oxy)C_{1-6}alkyl-phenyl, $-SO_kNH(C_{0-6}$alkyl), or -(C_{0-6}alkyl)$-SO_k-(C_{1-6}$alkyl), wherein the phenyl, heteroaryl or heterocycle is optionally substituted with halogen, -C_{1-6}alkyl, $-C_{1-6}$alkoxy, hydroxy, amino, or -C(O)-O-C_{1-6}alkyl, and wherein the alkyl or cycloalkyl is optionally substituted with 1-6 independently selected halogens or –OH, and wherein k is 0, 1, or 2;

R^3 is selected from H, halogen, CN, -C_{1-6}alkyl, -C_{3-6}cycloalkyl, nitro, -C(O)-C_{1-6}alkyl, -C(O)-O-C_{0-6}alkyl, -SO_n'NH(C_{0-6}alkyl), or -(C_{0-6}alkyl)-SO_n'-(C_{1-6}alkyl), O-C_{1-6}alkyl, O-C_{3-6}cycloalkyl, wherein n' is 0, 1, or 2 and wherein the alkyl and cycloalkyl is optionally substituted with 1-6 independently selected halogen or OH.

4. (Currently amended) ~~The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein~~

A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

Y is cyclopropyl-COOH;

Ar is phenyl.

R is H or $-C_{1-6}$alkyl;

R^1 is H, or $-C_{1-6}$alkyl, $-C_{3-6}$cycloalkyl, $-C_{1-6}$alkoxy, $-C_{2-6}$alkenyl, $-C_{3-6}$alkynyl, heteroaryl, or heterocycle group, optionally substituted with 1-3 independent

haloC1-6alkyl, -C1-6alkyl, –C1-6alkoxy, OH, amino, –(C0-6alkyl)–SOp–(C1-6alkyl), nitro, CN, =N-O-C1-6alkyl, -O-N=C1-6alkyl, or halogen substituents, wherein p is 0, 1 or 2;

R2 is H, halogen,-CN, -NO2, –C1-6alkyl, –C3-6cycloalkyl, -O- C3-6cycloalkyl, O-C1-6alkyl, O-C3-6cycloalkyl-C1-6alkyl(C3-6cycloalkyl)(C3-6cycloalkyl), –C1-6alkoxy, phenyl, heteroaryl, heterocycle, amino, –C(O)–C1-6alkyl, –C(O)–O–C1-6alkyl, –C1-6alkyl(=N-OH), -C(N=NOH)C1-6alkyl, –C0-6alkyl(oxy)C1-6alkyl-phenyl, –SOkNH(C0-6alkyl), or -(C0-6alkyl)–SOk–(C1-6alkyl), wherein the phenyl, heteroaryl or heterocycle is optionally substituted with halogen, -C1-6alkyl, –C1-6alkoxy, hydroxy, amino, or -C(O)-O-C1-6alkyl, and wherein the alkyl or cycloalkyl is optionally substituted with 1-6 independently selected halogens or –OH, and wherein k is 0, 1, or 2;

R3 is selected from H, halogen, CN, -C1-6alkyl, -C3-6cycloalkyl, nitro, -C(O)-C1-6alkyl, -C(O)-O-C0-6alkyl, -SOn'NH(C0-6alkyl), or -(C0-6alkyl)-SOn'-(C1-6alkyl), O-C1-6alkyl, O-C3-6cycloalkyl, wherein n' is 0, 1, or 2 and wherein the alkyl and cycloalkyl is optionally substituted with 1-6 independently selected halogen or OH.

5. (Cancelled)

6. (Original) The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R1 is –C3-6cycloalkyl optionally substituted with 1-3 independent -C1-6alkyl, –C1-6alkoxy, OH, amino, –(C0-6alkyl)–SOp–(C1-6alkyl), nitro, CN, =N-O-C1-6alkyl, -O-N=C1-6alkyl, or halogen substituents.

7. (Original) The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R is hydrogen.

8. (Original) The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R2 is hydrogen or –C1-3alkyl.

9. (Original) The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R1 is –C3-6cycloalkyl optionally substituted with methyl or halo; and

R is hydrogen.

10. (Original) The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^1 is cyclopropyl optionally substituted with methyl or halo; and

R and R^2 are hydrogen.

11-18 (Cancelled)

19. (Currently amended) ~~The compound according to claim 18 wherein~~ A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

R and R^3 are hydrogen,;

R^1 is $-C_{3-6}$cycloalkyl optionally substituted with methyl or halo, or $-C_{1-3}$alkyl optionally substituted with 1-3 halo; and

Ar is phenyl;

R^2 is hydrogen or halo; and

Y is $-CH_3$-C_{3-4}cycloalkyl –COOH or -C_{3-4}cycloalkyl-COOH.

20-28. (Cancelled)

29. (Currently amended) ~~A compound according to claim 2 wherein~~ A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

Ar is phenyl, pyridyl, pyrimidyl, indolyl, quinolinyl, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, or imidazolyl; or oxides thereof when Ar is a heteroaryl;

Y is -C_{3-6}cycloalkyl(C_{1-4}alkyl)$_m$-COOH, wherein the C_{3-6}cycloalkyl is optionally substituted with halogen, alkoxy, hydroxy or nitrile, and the (C_{1-4}alkyl) substituents are optionally linked to form a C_{3-6}cycloalkyl; wherein n is 0, 1, 2, 3 or 4, m is 0, 1;

R is H or –C_{1-6}alkyl;

R^1 is H, or –C_{1-6}alkyl, –C_{3-6}cycloalkyl, –C_{1-6}alkoxy, –C_{2-6}alkenyl, –C_{3-6}alkynyl, heteroaryl, or heterocycle group, optionally substituted with 1-3 independent haloC_{1-6}alkyl, -C_{1-6}alkyl, –C_{1-6}alkoxy, OH, amino, –(C_{0-6}alkyl)–SO_p–(C_{1-6}alkyl), nitro, CN, =N-O-C_{1-6}alkyl, -O-N=C_{1-6}alkyl, or halogen substituents, wherein p is 0, 1 or 2;

R^2 is H, halogen,-CN, -NO_2, –C_{1-6}alkyl, –C_{3-6}cycloalkyl, -O- C_{3-6}cycloalkyl, O-C_{1-6}alkyl, O-C_{3-6}cycloalkyl-C_{1-6}alkyl(C_{3-6}cycloalkyl)(C_{3-6}cycloalkyl), –C_{1-6}alkoxy, phenyl, heteroaryl, heterocycle, amino, –C(O)–C_{1-6}alkyl, –C(O)–O–C_{1-6}alkyl, –C_{1-6}alkyl(=N-OH), -C(N=NOH)C_{1-6}alkyl, –C_{0-6}alkyl(oxy)C_{1-6}alkyl-phenyl, –SO_kNH(C_{0-6}alkyl), or -(C_{0-6}alkyl)–SO_k–(C_{1-6}alkyl), wherein the phenyl, heteroaryl or heterocycle is optionally substituted with halogen, -C_{1-6}alkyl, –C_{1-6}alkoxy, hydroxy, amino, or -C(O)-O-C_{1-6}alkyl, and wherein the alkyl or cycloalkyl is optionally substituted with 1-6 independently selected halogens or –OH, and wherein k is 0, 1, or 2;

R^3 is selected from H, halogen, CN, -C_{1-6}alkyl, -C_{3-6}cycloalkyl, nitro, -C(O)-C_{1-6}alkyl, -C(O)-O-C_{0-6}alkyl, -SO_n'NH(C_{0-6}alkyl), or -(C_{0-6}alkyl)-SO_n'-(C_{1-6}alkyl), O-C_{1-6}alkyl, O-C_{3-6}cycloalkyl, wherein n' is 0, 1, or 2 and wherein the alkyl and cycloalkyl is optionally substituted with 1-6 independently selected halogen or OH.

30. (Previously added) A compound which is:



or a pharmaceutically acceptable salt thereof.

31. (Previously added) A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 30 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

32-36 (Cancelled)